Cell therapy (CAR-T) · Kills target cells, directed at CD19 · developed by Fate Therapeutics
FT819 is an off-the-shelf allogeneic T-cell therapy derived from an induced pluripotent stem cell line, engineered to express a CD19-directed chimeric antigen receptor with CD28 and CD3-zeta signaling domains. The CAR T-cells bind CD19-expressing cells and lyse them, and the T-cell receptor is eliminated to reduce the risk of graft versus host disease. It is being studied in lupus nephritis and systemic lupus erythematosus.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07570862 | Phase 2 | Lupus Nephritis | Recruiting | FATE |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Lupus NephritisLupus Nephritis - WHO Class IIILupus Nephritis - WHO Class IVSLE - Systemic Lupus ErythematosusSystemic Lupus Erythematosus
Updated Nov 15, 2026. Something wrong or missing? Report it on the FATE page.
See FATE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
FATE catalysts and pipeline →